WEXFORD, Pennsylvania., October 9, 2023 /PRNewswire/ — Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) (“Coeptis” or “the Company”), a biopharmaceutical company developing innovative cell therapy platforms against cancer, announced today that Dan YeraceDirector and Vice President of Operations, will participate in a panel entitled “Ambitious Innovation: Emerging Cell and Gene Therapies” at the BioFlorida Conference on Thursday October 12th Since 11:50 a.m.-12:50 p.m..
Details of the roundtable are as follows:
| Event: | BioFlorida Conference |
| Date and hour : | October 12, 2023, 11:50 a.m. EDT |
| Panel title | Ambitious innovation: emerging cell and gene therapies |
| Location: | Sawgrass Marriott Golf Resort & Spa, Ponte Vedra Beach, Florida |
About Coeptis Therapeutics Holdings, Inc.
Coeptis Therapeutics Holdings, Inc., together with its subsidiaries, including Coeptis Therapeutics, Inc. and Coeptis Pharmaceuticals, Inc. (collectively “Coeptis”), is a biopharmaceutical company developing innovative cancer cell therapy platforms that have the potential to disrupt conventional treatments. paradigms and improve patient outcomes. Coeptis’ product portfolio and rights are highlighted by licensed assets from Deverra Therapeutics, including an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage unmodified natural killer cell therapy technology. In addition, Coeptis is developing universal, multi-antigen CAR T technology under license from University of Pittsburgh (SNAP-CAR), as well as the GEAR™ cell therapy and companion diagnostic platforms, which Coeptis is developing with VyGen-Bio and leading medical researchers at Karolinska Institutet. Coeptis’ business model is designed around maximizing the value of its existing product portfolio and rights through licensing agreements, licensing agreements and co-development relationships, as well as entering into strategic partnerships to expand its rights and product offerings, particularly those targeting cancer. The company is headquartered in Wexford, Pennsylvania. For more information about Coeptis, visit https://coeptistx.com/.
Caution Regarding Forward-Looking Statements
This press release and statements by our management made in connection therewith contain or may contain “forward-looking statements” (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended). Forward-looking statements include statements regarding our plans, objectives, goals, strategies, future events or performance and underlying assumptions, as well as other statements that are not statements of historical fact. When we use words such as “may”, “will”, “intend”, “should”, “believe”, “expect”, “anticipate”, “plan”, “estimate” or similar expressions that do not relate solely to historical matters, we make forward-looking statements. Forward-looking statements are not guarantees of future performance and involve important risks and uncertainties that may cause actual results to differ materially and possibly materially from our expectations discussed in the forward-looking statements. Factors that could cause such differences include, but are not limited to: (1) the inability to maintain the listing of the Company’s securities on the Nasdaq Capital Market; (2) the risk that the integration of the Deverra licensed assets disrupts the Company’s current plans and operations; (3) the inability to recognize the expected benefits of the newly authorized assets, which may be affected by, among other things, competition, the ability of the Company to grow and manage its growth economically and to hire and retain employees key employees; (4) risks that the Company’s products in development or newly licensed assets fail clinical trials or are not approved by the United States Food and Drug Administration or other applicable regulatory authorities; (5) costs related to the integration of the newly authorized Deverra assets and the pursuit of contemplated asset development paths; (6) changes in applicable laws or regulations; (7) the possibility that the Company may be adversely affected by other economic, business and/or competitive factors; and (8) the impact of the COVID-19 global pandemic on any of the above and other risks and uncertainties identified in the Company’s filings with the Securities and Exchange Commission (the “SEC “). The foregoing list of factors is not exclusive. All forward-looking statements are subject to significant uncertainties and risks, including, without limitation, risks contained or expected to be contained in the reports and other documents filed by the Company with the SEC. For these and other reasons, investors are cautioned not to place undue reliance on the forward-looking statements contained in this press release. Additional factors are discussed in the Company’s filings or to be filed with the SEC, which can be found at:www.sec.gov. We undertake no obligation to publicly revise these forward-looking statements to reflect events or circumstances occurring after the date hereof, except as required by applicable laws, regulations or rules.
CONTACTS
Coeptis Therapeutics, Inc.
Andy Galysenior vice president of communications
(email protected)
Tiberend Strategic Advisors, Inc.
Investors
Daniel Kontoh Boateng
(email protected)
Media
David Schemelia
(email protected)
SOURCE Coeptis Therapeutics
